Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: CYBERKEN who wrote (14001)	1/31/1998 9:48:00 AM
From: tonyt	Respond to of 32384

> Considerable lack of wine bets. Too busy 'whining', I guess. > Nothing but the murky bottom of Lake Ligand. Let us know if you see the Titanic down there :-) > As for me, I'm grabbing more warrants and floating back to the surface. Watch out, they could prove to be an anchor, not a life saver.

To: CYBERKEN who wrote (14001)	1/31/1998 4:42:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

> More posts about Big Pharma mergers than Ligand (sorry Henry). Over a dozen iterations of the same story in the past 24 hrs alone.

To: CYBERKEN who wrote (14001)	2/2/1998 7:49:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

> More posts about Big Pharma mergers than Ligand (sorry Henry). Get ready for more of the same today.

To: CYBERKEN who wrote (14001)	2/2/1998 8:01:00 AM
From: tonyt	Respond to of 32384

Maybe Asia will pull LGND out of its slump (...if not, one less excuse): "Pent-up demand for stocks following a week of holidays sent Asian-Pacific equities and currency markets surging Monday. Hong Kong's Hang Seng jumped 14.3%, lifted by foreign buying." BTW, I suprised no one posted the positive Barron's article.

To: CYBERKEN who wrote (14001)	2/2/1998 8:31:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

CNBC finally got around to talking about Biotechs. Joe Kernan and David Faber began talking about more mergers. They said that smaller companies like WLA, SGP, and PNU would be pushed to consolidate, but larger companies like MRK, BMY and AHP would also be impacted. They again mentioned R&D as a major driver and cited SBH's early deal with HGSI (genomics) as well as AFFX's gene's on chips. These new technologies will lead to many new research avenues which will be very expensive. Of course the big boys are already familiar with LGND. PFE, GLX, AGN, ABT, AHP, SBH, Sankyo, and LLY have already taken equity positions. LGND's drug discovery is more advanced and compounds are much closer to market (3-4 NDAs slated for this year including one this quarter) and companies like LLY are jumping into the rexinoids with both feet. Similarly, LGND has SERM programs with PFE, AHP, and LLY, so even tighter niches are being actively persued by multiple partners. The big boys will move up big time today, but the affect will trickle down to the Biotechs when the street gets a chance to access the implications.